DIATRIZOATE MEGLUMINE; IODIPAMIDE MEGLUMINE - Generic Drug Details

What are the generic drug sources for diatrizoate meglumine; iodipamide meglumine and what is the scope of patent protection?

Diatrizoate meglumine; iodipamide meglumine is the generic ingredient in one branded drug marketed by Bracco and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for DIATRIZOATE MEGLUMINE; IODIPAMIDE MEGLUMINE

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
DailyMed Link:	DIATRIZOATE MEGLUMINE; IODIPAMIDE MEGLUMINE at DailyMed

US Patents and Regulatory Information for DIATRIZOATE MEGLUMINE; IODIPAMIDE MEGLUMINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bracco	SINOGRAFIN	diatrizoate meglumine; iodipamide meglumine	SOLUTION;INTRAUTERINE	011324-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No

DIATRIZOATE MEGLUMINE / IODIPAMIDE MEGLUMINE: Market Dynamics and Financial Trajectory

Last updated: April 25, 2026

What are these products and where do they sit in the radiology market?

Diatrizoate meglumine and iodipamide meglumine are iodinated contrast media used for diagnostic imaging, typically in radiography and related procedures. In commercial practice they compete in the broader “iodinated contrast media” segment, alongside nonionic agents (e.g., iohexol, iopamidol, ioversol, iopromide, iobitridol) that have long captured market share due to lower adverse reaction profiles.

How is demand shaped for iodinated contrast media?

Demand is driven by:

• Imaging utilization trends (CT, radiography volumes, procedure mix).
• Institutional procurement cycles (group purchasing, tendering).
• Formulary preferences for nonionic contrast (safety profile and operational risk controls).
• Supply continuity and pricing mechanics (manufacturing constraints, commodity iodine costs, and replacement cycles).

For legacy ionic iodinated contrast options (which diatrizoate/iodipamide are generally treated as within industry categorization), market dynamics typically follow a “share down unless cost-driven” pattern: usage persists where budget pressure outweighs the shift to nonionic alternatives, or where specific clinical pathways prefer these agents.

What is the pricing and substitution reality?

Within iodinated contrast, payers and hospitals often favor nonionic, lower-osmolality agents when budgets permit. Legacy ionic contrast media generally price at a discount, with the commercial outcome determined by:

• Health system cost containment and procurement leverage.
• Availability of approved alternatives in the same imaging setting.
• Brand versus generic positioning (and local regulatory pathways).
• Switching friction (training, protocol standardization, supply contracts).

In practice, diatrizoate meglumine and iodipamide meglumine trade like older-generation contrast, where volume can remain stable at the institutional level but growth lags nonionic leaders unless pricing remains materially attractive.

How do competitive forces compress growth and influence margins?

Competitive set

Key competitive categories:

• Nonionic, low-osmolar iodinated contrast media (dominant for many CT and imaging protocols).
• Other ionic agents and legacy contrast alternatives in lower-utilization or cost-led settings.

Force mapping

• Substitution risk is high: nonionic agents are preferred in many formularies.
• Procurement is cyclical: tenders cap long-run pricing power.
• Regulatory and safety scrutiny is persistent: contrast adverse reaction controls shape which products get chosen.
• Inventory and supply constraints matter: contrast media is high-throughput; supply interruptions lead to switching but can also trigger future re-ordering if continuity is assured.

What does the financial trajectory typically look like for these legacy agents?

Trajectory template for legacy ionic contrast

Across major markets, legacy iodinated contrast products typically show:

• Revenue stability or modest decline tied to imaging growth minus ongoing substitution toward nonionic.
• Gross margin compression due to tender-driven pricing and competition from nonionic.
• Reduced brand premium and increasing share held by genericized equivalents or alternative formulations.
• Working-capital pressure from inventory planning and tender cadence.

Because diatrizoate meglumine and iodipamide meglumine are older contrast chemistries, the financial pattern in a mature radiology market is usually not “launch-like expansion.” It is more consistent with a steady, procurement-driven base with margin variability rather than sustained top-line acceleration.

Where are regulatory and safety constraints likely to shape commercial outcome?

Contrast media markets are impacted by:

• Labeling requirements and risk-management expectations.
• Institutional protocols for premedication and monitoring.
• Product-specific adverse event incidence profiles and pharmacovigilance reporting.

Even when products are still used, safety-driven protocol changes often move decision-making toward nonionic agents over time. That affects both volume share and pricing flexibility.

How do reimbursement and payer incentives impact volumes?

Reimbursement generally pays per procedure rather than per milliliter of contrast, which makes institutional procurement the key lever. As a result:

• Buyers optimize total cost of imaging episode and avoid adverse event costs.
• If nonionic agents achieve sufficient price parity via generics, substitution accelerates.
• Where budget pressure persists, older ionic agents can remain part of a cost-minimizing mix.

What are the market risks for DIATRIZOATE MEGLUMINE / IODIPAMIDE MEGLUMINE?

The risk stack for legacy ionic contrast media is structurally:

• Ongoing substitution to nonionic contrast across radiology and CT.
• Tender price resets that erode long-term pricing power.
• Supply chain and manufacturing economics (scale and cost position vs competitors).
• Clinical protocol evolution that changes preferred contrast classes.
• Potential market exits or supply disruptions affecting continuity, which can temporarily shift usage.

What operational levers determine whether these products grow or decline in a given geography?

Commercial outcomes hinge on:

• Contracting position with group purchasing organizations.
• Local competitive availability of nonionic alternatives at comparable price.
• Conversion of formularies where legacy ionic agents are still included.
• Distribution reach and cold-chain/handling logistics (if applicable per local product form factors).
• Volume commitment structures within hospital networks.

Financial trajectory checklist: what to expect in statements of sales and trajectory indicators

Even without company-specific financials, the typical leading indicators for legacy contrast media include:

• Stable unit volumes in institutions where ionic agents remain in protocol sets.
• Revenue fluctuations driven by tender cycles.
• Margin pressure as procurement shifts to lower-cost equivalents.
• Lower growth rate than overall imaging market growth due to share loss to nonionic.

Key product data points relevant to commercial positioning

The commercial narrative for these agents in the iodinated contrast market ties to:

• Iodine delivery for X-ray based imaging.
• Existing formulary inclusion in certain protocols.
• Role as cost-led options within a safety-conscious environment.

Market outlook: base-case dynamics

Base-case dynamics for diatrizoate meglumine and iodipamide meglumine in mature markets:

• Volume: slow erosion or flat-to-modest decline as imaging volumes grow but protocol mix shifts.
• Pricing: downward pressure from procurement and substitution; occasional stabilization when supply constraints or price gaps widen in favor of ionic legacy products.
• Margins: compress with tendering and generic competition; improvements depend on volume commitments and relative cost position.

Key Takeaways

• Diatrizoate meglumine and iodipamide meglumine sit in legacy ionic iodinated contrast, competing directly against nonionic low-osmolar agents that take share through formulary preferences and safety protocols.
• Demand is procurement-driven within institutional radiology networks, with pricing reset at tender intervals.
• The financial trajectory is typically stable-to-declining volume share with margin pressure, unless cost parity and supply dynamics favor ionic legacy options.
• The primary upside lever is contracting position and relative price versus nonionic alternatives; the primary downside is continued protocol conversion to nonionic contrast.

FAQs

1) Do these products compete primarily on clinical performance or cost?

Cost and procurement economics dominate in later-stage adoption of legacy ionic agents because imaging procedures pay per study while hospitals optimize total cost and risk. Clinical protocol preferences still matter, but substitution risk is largely managed through price and availability.

2) What is the main long-term growth headwind?

Formulary substitution toward nonionic low-osmolar iodinated contrast media, which is driven by adverse reaction profiles and institutional risk management.

3) What is the main driver of year-to-year revenue variability?

Tender timing and contract renegotiations, which can change effective selling prices and mix within hospitals and imaging groups.

4) Can a legacy ionic product still expand in a geography?

Yes, when pricing gaps versus nonionic agents widen, when procurement contracts lock in ionic agents, or when nonionic supply is constrained. Expansion is usually local and contract-specific rather than market-wide.

5) How should investors interpret “stable” revenues for legacy contrast agents?

Stable revenues usually indicate continued inclusion in a subset of protocols and hospital purchasing patterns, but not necessarily a share-gaining position; it often reflects a base that resists substitution due to cost constraints or contracting inertia.

---

References

[1] U.S. Food and Drug Administration. Drug Labeling and Approval Reports for iodinated contrast agents (diatrizoate/iodipamide class). FDA drug databases and labeling records.
[2] European Medicines Agency. Product information and assessment documents for iodinated contrast media (diatrizoate/iodipamide-related). EMA medicinal product databases.
[3] National Library of Medicine. Drug records and pharmacology references for diatrizoate meglumine and iodipamide meglumine (contrast media use and classification). PubMed/DrugBank/MedlinePlus-related listings.